In partnership with PHD Pharmaceuticals Ireland, Rhei Life successfully delivered a life-saving medicine used in Covid-19 protocol treatment to the Italian market.

„ In the event of a global pandemic such as COVID-19, almost all pharmaceutical markets globally experienced vulnerability to drug shortages. The Italian market is one of the first markets in Europe to be hit with that negative trend. We are particularly proud that our company exported to Italy Propofol (a sedative-hypnotic agent widely used for both induction and maintenance of sedation in critical care units), a medicine that was used in Italian hospitals. In addition, we are constantly working with our Italian partner on identifying whether there are ongoing shortages on the market “, said David Stakić, Rhei Life Market Access Manager.

Propofol is used as an “induction agent”, a drug that causes loss of consciousness, for general anaesthesia in major surgeries. In lower doses it is also used for “conscious sedation” of patients getting procedures on an outpatient basis at ambulatory surgery centres. Propofol injection is used to help you relax, or sleep before and during surgery or other medical procedures. This medicine is an anaesthetic and a sedative. Propofol may also be used to sedate coronavirus (COVID-19) patients who need mechanical ventilation in the intensive care unit (ICU).